An Assessment of Potential Drug-Drug Interactions in Hypertensive Patients in a Tertiary Care Hospital

INTRODUCTION: Hypertension, also known as high or raised blood pressure, is a global public health issue. It contributes to the burden of heart disease, stroke and kidney failure, and premature mortality and disability. It disproportionately affects populations in low and middle income countries where health systems are weak. Hypertension rarely causes symptoms in the early stages and many people go undiagnosed. Those who are diagnosed may not have access to treatment and may not be able to successfully control their illness over the long term. AIM OF THE STUDY: To an assessment of potential drug-drug interactions in hypertensive patients in a tertiary care hospital. OBJECTIVES: 1. To identify the prevalence of potential drug-drug interactions, in hypertensive patients. 2. To pick out the types and severity of PDDIs. 3. To analyses the hazard which it became associated with drug interaction in hypertensive patients. 4. To identify the drug that most commonly implanted in drug-drug interactions and to understand the antihypertensive drug mainly interacting with different drugs. CONCLUSION: Our study concluded that the overall incidence of PDDIs was terribly high in hypertensive patients. The PDDIs were found to be more in females compared to males, it had been found that incidence of pDDIs was associated with older age, polypharmacy and accrued lengths of hospital stay. the majority of interactions were pharmacodynamic in nature, having a moderate interactions risk. the foremost of the common pDDIs were between aspirin and clopidogrel followed by amlodipine and simvastatin. Clinical pharmacist ought to have role of regular monitoring of drug therapy in identifying and preventing the medications that have the potential to cause drug-drug interactions thereby minimizing the undesirable outcomes in drug medical care and improving the quality of care. Use of electronic database systems as decision support tools, automated prescription alerts to doctors, conducting educational programs and watchful towards drug choice will decrease the negative outcomes of pDDIs. therefore a daily review of the drug therapy by a clinical pharmacist during a multidisciplinary team might help to identify and prevent potential drug-drug interactions particularly in patients with chronic disease receiving multiple associated with their co-morbid conditions. These can successively help to optimize drug therapy, improve the quality of care and condense the undesirable outcomes within the patient drug therapy